MAXCYTE, INC.
MXCT US57777K1060
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40% | -50% | -8% | -17% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Masoud Maher CEO |
1.37 USD |
75,000 Bought |
102,915 USD |
13/08/2025 | 13/08/2025 |
| Erck Stanley C |
1.37 USD |
100,000 Bought |
137,220 USD |
13/08/2025 | 13/08/2025 |
| Douglas Richard |
1.39 USD |
80,000 Bought |
111,040 USD |
13/08/2025 | 13/08/2025 |
| Brooke William W |
1.29 USD |
50,000 Bought |
64,500 USD |
13/08/2025 | 13/08/2025 |
| Swirsky Douglas J CFO |
1.29 USD |
50,000 Bought |
64,500 USD |
13/08/2025 | 13/08/2025 |
| Hemrajani Rekha |
2.09 USD |
10,684 Sold |
22,378 USD |
25/06/2025 | 25/06/2025 |
| Swirsky Douglas J CFO |
3.18 USD |
6,939 Sold |
22,061 USD |
18/03/2025 | 18/03/2025 |
| Sandoval David I. SR OFF |
3.18 USD |
353 Sold |
1,122 USD |
18/03/2025 | 18/03/2025 |
| Soleymannezhad Ali CCO |
3.18 USD |
1,211 Sold |
3,850 USD |
18/03/2025 | 18/03/2025 |
| Johnston John Joseph O |
4.65 USD |
3,000 Sold |
13,935 USD |
27/01/2025 | 27/01/2025 |